TG Therapeutics, Inc. (TGTX) Expected to Announce Quarterly Sales of $40,000.00
Equities analysts expect TG Therapeutics, Inc. (NASDAQ:TGTX) to post sales of $40,000.00 for the current fiscal quarter, Zacks Investment Research reports. Two analysts have made estimates for TG Therapeutics’ earnings. TG Therapeutics also posted sales of $40,000.00 during the same quarter last year. The business is scheduled to announce its next earnings results on Monday, November 6th.
On average, analysts expect that TG Therapeutics will report full year sales of $40,000.00 for the current financial year, with estimates ranging from $150,000.00 to $160,000.00. For the next fiscal year, analysts forecast that the business will report sales of $3.44 million per share, with estimates ranging from $150,000.00 to $10.00 million. Zacks’ sales calculations are an average based on a survey of analysts that that provide coverage for TG Therapeutics.
TG Therapeutics (NASDAQ:TGTX) last issued its quarterly earnings results on Wednesday, August 9th. The biopharmaceutical company reported ($0.45) EPS for the quarter, beating the consensus estimate of ($0.46) by $0.01. The company had revenue of $0.04 million for the quarter, compared to the consensus estimate of $0.04 million. TG Therapeutics had a negative net margin of 68,806.59% and a negative return on equity of 154.02%.
A number of research firms recently issued reports on TGTX. BidaskClub raised shares of TG Therapeutics from a “sell” rating to a “hold” rating in a research report on Thursday. FBR & Co reissued a “buy” rating on shares of TG Therapeutics in a research report on Saturday, June 17th. Zacks Investment Research downgraded shares of TG Therapeutics from a “hold” rating to a “sell” rating in a research report on Saturday, August 12th. Jefferies Group LLC reissued a “buy” rating and set a $23.00 target price on shares of TG Therapeutics in a research report on Monday, June 5th. Finally, ValuEngine raised shares of TG Therapeutics from a “sell” rating to a “hold” rating in a research report on Friday, June 2nd. One analyst has rated the stock with a sell rating, two have assigned a hold rating and ten have given a buy rating to the company. TG Therapeutics currently has a consensus rating of “Buy” and an average price target of $25.40.
In other TG Therapeutics news, CFO Sean A. Power sold 59,976 shares of the stock in a transaction that occurred on Monday, June 19th. The shares were sold at an average price of $11.09, for a total value of $665,133.84. Following the completion of the sale, the chief financial officer now owns 477,464 shares of the company’s stock, valued at $5,295,075.76. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. 16.70% of the stock is owned by company insiders.
Hedge funds have recently modified their holdings of the stock. Legal & General Group Plc increased its stake in shares of TG Therapeutics by 4.1% in the first quarter. Legal & General Group Plc now owns 9,801 shares of the biopharmaceutical company’s stock valued at $113,000 after buying an additional 384 shares during the period. BB&T Securities LLC purchased a new stake in shares of TG Therapeutics during the first quarter valued at about $121,000. Hollencrest Securities LLC purchased a new stake in shares of TG Therapeutics during the second quarter valued at about $121,000. Thompson Davis & CO. Inc. purchased a new stake in shares of TG Therapeutics during the first quarter valued at about $154,000. Finally, Fox Run Management L.L.C. purchased a new stake in shares of TG Therapeutics during the second quarter valued at about $156,000. 46.53% of the stock is owned by institutional investors.
TG Therapeutics (TGTX) opened at 11.45 on Friday. The company’s market capitalization is $713.45 million. The company’s 50-day moving average is $11.09 and its 200 day moving average is $10.47. TG Therapeutics has a one year low of $4.10 and a one year high of $15.35.
TG Therapeutics Company Profile
TG Therapeutics, Inc (TG) is a biopharmaceutical company focused on the acquisition, development and commercialization of treatments for B-cell malignancies and autoimmune diseases. As of December 31, 2016, the Company was developing two therapies targeting hematological malignancies. TG-1101 (ublituximab) is a glycoengineered monoclonal antibody that targets a specific epitope on the cluster of differentiation (CD20) antigen found on mature B-lymphocytes.
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Stock Ratings for TG Therapeutics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for TG Therapeutics Inc. and related stocks with our FREE daily email newsletter.